• S M de Boer, B G Wortman, T Bosse, M E Powell, N Singh, H Hollema, G Wilson, M N Chowdhury, L Mileshkin, J Pyman, D Katsaros, S Carinelli, A Fyles, C M McLachlin, C Haie-Meder, P Duvillard, R A Nout, K W Verhoeven-Adema, H Putter, C L Creutzberg, Smit V T H B M VTHBM Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., and for PORTEC Study Group.
• Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: s.m.de_boer.onco@lumc.nl.
• Ann. Oncol. 2018 Feb 1; 29 (2): 424-430.

BackgroundIn the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) with or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2). Pathology review was required before patient enrolment. The aim of this analysis was to evaluate the role of central pathology review before randomisation.Patients And MethodsA total of 1295 cases underwent pathology review to confirm HR-EC in the Netherlands (n = 395) and the UK (n = 900), and for 1226/1295 (95%) matching review and original reports were available. In total, 329 of these patients were enrolled in the PORTEC-3 trial: 145 in the Netherlands and 184 in the UK, comprising 48% of the total PORTEC-3 cohort of 686 participants. Areas of discrepancies were evaluated, and inter-observer agreement between original and review opinion was evaluated by calculating the kappa value (κ).ResultsIn the 1226 pathology reviews, 6356 selected items were evaluable for both original and review pathology. In 43% of cases at least one pathology item changed after review. For 102 patients (8%), this discrepancy led to ineligibility for the PORTEC-3 trial, most frequently due to differences in the assessment of histological type (34%), endocervical stromal involvement (27%) and histological grade (19%). Lowest inter-observer agreement was found for histological type (κ = 0.72), lymph-vascular space invasion (κ = 0.72) and histological grade (κ = 0.70).ConclusionCentral pathology review by expert gynaeco-pathologists changed histological type, grade or other items in 43% of women with HR-EC, leading to ineligibility for the PORTEC-3 trial in 8%. Upfront pathology review is essential to ensure enrolment of the target trial-population, and to avoid over- or undertreatment, especially when treatment modalities with substantial toxicity are involved. This study is registered with ISRCTN (ISRCTN14387080, www.controlled-trials.com) and with ClinicalTrials.gov (NCT00411138).© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

19 keywords...

hide…